Pharmaceuticals News and Research

RSS

New pre-clinical data on Rexahn's RX-3117 study to be presented at AACR meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present new pre-clinical data on its oncology compound RX-3117 during a poster session at the American Association for Cancer Research (AACR) 103rd Annual Meeting being held in Chicago, Illinois, March 31 - April 4, 2012, at the McCormick Place Convention Center.

28 Mar 2012

UT Southwestern researcher wins prestigious award from International Atherosclerosis Society

Dr. Helen Hobbs, a preeminent researcher on the genetics of cholesterol metabolism at UT Southwestern Medical Center, has won a prestigious award from the International Atherosclerosis Society.

28 Mar 2012

Top-line results from two Targacept TC-6987 Phase 2 studies on asthma, type 2 diabetes

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced top-line results from two separate exploratory Phase 2 studies of its product candidate TC-6987 conducted in the United States, one in asthma and one in type 2 diabetes.

28 Mar 2012

Experimental drugs from Sanofi and Regenron cut cholesterol in a new way

An experimental drug that acts in a novel way to lower cholesterol proved even more effective than statins and had few undesirable side effects, newly released data shows. The drug acts by modifying the way cholesterol levels are naturally controlled. A protein produced in the liver helps limit the amount of LDL, or “bad” cholesterol, that liver cells can remove from the bloodstream. The new drug, called REGN727, is a monoclonal antibody, made in a laboratory, that blocks the action of that protein.

27 Mar 2012

Rivaroxaban found safe and effective in pulmonary embolism

Rivaroxaban has been found to be effective in the prevention of venous thromboembolism (VTE) after orthopedic surgery, for the prevention of stroke in AF (Atrial fibrillation) patients, and as additional therapy to conventional antiplatelet therapy in ACS (Acute coronary syndrome) patients.

27 Mar 2012

Boniva generics receive FDA approval for treatment, prevention of osteoporosis

The U.S. Food and Drug Administration today approved the first generic versions of Boniva (ibandronate) tablets, a once-monthly product to treat or prevent osteoporosis in women after menopause.

27 Mar 2012

Pfizer to present data on ADCs at AACR 2012

Pfizer Oncology will present data from a variety of preclinical and clinical studies of Pfizer's early-stage compounds, including data from Pfizer's investigational antibody-drug conjugate (ADC) portfolio and research evaluating several molecules targeting novel pathways that play a crucial role in basic cellular functions, at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, IL, from March 31-April 4.

27 Mar 2012

Report explores expanding influence of BRICS on global health and development

Brazil, Russia, India, China and South Africa are injecting new resources, momentum and innovation into efforts to improve health in the world's poorest countries, according to a report released on the eve of the 2012 BRICS Summit. Coming as many traditional donors reduce or slow their spending, the report explores the expanding influence of the BRICS on global health and development.

27 Mar 2012

New method uses E. coli bacteria to engineer human therapeutic glycoproteins

Escherichia coli - a bacteria considered the food safety bane of restaurateurs, grocers and consumers - is a friend. Cornell University biomolecular engineers have learned to use E. coli to produce sugar-modified proteins for making pharmaceuticals cheaper and faster.

27 Mar 2012

Teva, IVAX receive FDA approval for generic Lexapro to treat depression and GAD

The U.S. Food and Drug Administration today approved the first generic Lexapro (escitalopram tablets) to treat both depression and generalized anxiety disorder in adults.

27 Mar 2012

Hapten licenses HPT-721 to prevent poison ivy dermatitis

Hapten Sciences Inc. of Memphis, Tenn., has licensed a compound developed by ElSohly Laboratories Inc. and University of Mississippi pharmaceutical researchers to prevent reactions to poison ivy, oak and sumac.

27 Mar 2012

Researchers launch major aspirin trial to eradicate H. pylori

Researchers have launched a major clinical trial to investigate whether eliminating a common stomach bug could help to make taking aspirin safer in some patients.

27 Mar 2012

FDA issues Complete Response letter to MAP's NDA for LEVADEX

MAP Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for LEVADEX (dihydroergotamine) inhalation aerosol.

27 Mar 2012

India’s TB treatment inadequate raising risk of drug resistance

India suffers from inadequate government-run tuberculosis (TB) treatment programs and a lack of regulation of the sale of drugs against TB. This has led to the rise in number of drug-resistant cases that are difficult to treat, health activists said Friday.

26 Mar 2012

Valeant signs agreement to acquire Natur Produkt

Valeant Pharmaceuticals International, Inc. announced today that Valeant has signed an agreement to acquire Natur Produkt International, JSC, a specialty pharmaceutical company in Russia.

26 Mar 2012

EMA accepts Arena's lorcaserin MAA for weight control

Arena Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has accepted the filing of a Marketing Authorization Application (MAA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition.

26 Mar 2012

FDA approves Teva's QNASL nasal aerosol corticosteroid

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved QNASL Nasal Aerosol, a new, "dry" nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older.

26 Mar 2012

Theracurmin shows positive impact on human diastolic functions

The research group led by Dr. Koji Hasegawa, Director of the Translational Research Division at the National Hospital Organization Kyoto Medical Center and Dr. Tatsuya Morimoto, Professor at the Molecular Medicine School of Pharmaceutical Sciences, University of Shizuoka, announced today based on the recent human clinical trials, that Theracurmin has continuously shown positive impact on human diastolic functions.

26 Mar 2012

USPTO issues patent to Inovio's SynCon H1N1 influenza vaccine

Inovio Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 8,133,723, covering Inovio's SynCon universal vaccine related to H1N1 influenza.

26 Mar 2012

$Economic burden of fragility fractures in Europe far exceeds previous estimates$

Economic burden of fragility fractures in Europe far exceeds previous estimates

Researchers at the European Congress of Osteoporosis & Osteoarthritis in Bordeaux have presented new data * which shows that the economic burden of fragility fractures in the 27 member states of the European Union far exceeds previous estimates, with hip fractures accounting for around 55% of costs.

26 Mar 2012